IFNG and neoplasm: Investigation of biomarkers of responsiveness to this combination therapy is of interest, including the role of tumor MHC Class I and PD-L1 level, capacity to mount a systemic IFNγ response, expansion of neoantigen-reactive T cells, and TCR clonality.